Companies / Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc.
Nasdaq: RAPPCIK 2012593BOSTON, MA
Financials
Ownership
48.0M shares outstanding · as of Aug 3, 2026
Ownership
| Insiders | 1.20% | 576,976 |
| 10%+ / strategic | 11.31% | 5,425,070 |
| Institutions | 94.79% | 45,480,939 |
| Public float | 0.00% | 0 |
Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 10
View all →| Insider | % of shares | Shares |
|---|---|---|
Ceesay AbrahamCEOChief Executive Officer · Director | 1.20% | 576,976 |
Bredt DavidFormerChief Scientific Officer | 0.82% | 393,075 |
Yeleswaram KrishnaswamyFormerChief Development Officer | 0.60% | 286,876 |
Gault CherylFormerChief Operating Officer | 0.33% | 159,914 |
Healy JamesDirector | — | — |
Ignelzi Troy A.Chief Financial Officer | — | — |
Maraganore JohnDirector | — | — |
Paul Steven MDirector | — | — |
Perez Robert JDirector | — | — |
Sevigny JeffreyChief Medical Officer | — | — |
Institutional holders 145
View all →| Holder | Value | % of shares |
|---|---|---|
| $216.48M | 14.87% | |
| $215.77M | 14.82% | |
| $116.67M | 7.77% | |
| $112.50M | 5.63% | |
| $103.23M | 7.09% | |
| $91.85M | 6.31% | |
| $91.08M | 6.26% | |
| $57.78M | 3.97% | |
| $55.15M | 3.79% | |
| $54.14M | 3.72% |
Activity
InsidersInstitutions
What insiders are doing in this stock (Form 4).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | Yeleswaram Krishnaswamy Executive | Sell | Common Stock | $303.4K | -10K -3.41% | 286,876 0.60% of shares | medium |
| Jan 15, 2026 | Bredt David Executive | Sell | Common Stock | $222.7K | -8K -2.05% | 395,775 0.82% of shares | medium |
| Mar 30, 2026 | Gault Cheryl Executive | Sell | Common Stock | $200.8K | -7K -4.21% | 162,753 0.34% of shares | medium |
| Dec 31, 2025 | Bredt David Executive | Sell | Common Stock | $197.3K | -7K -1.60% | 404,075 0.84% of shares | medium |
| Feb 17, 2026 | Bredt David Executive | Sell | Common Stock | $156.3K | -5K -1.37% | 389,275 0.81% of shares | medium |
| Jan 20, 2026 | Ceesay Abraham CEO | Sell | Common Stock | $152.3K | -6K -1.03% | 562,080 1.17% of shares | medium |
| Jan 20, 2026 | Ceesay Abraham CEO | Sell | Common Stock | $132.7K | -5K -16.45% | 25,812 0.05% of shares | medium |
| Feb 18, 2026 | Ceesay Abraham CEO | Sell | Common Stock | $103.2K | -4K -0.63% | 558,528 1.16% of shares | medium |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Cormorant Asset Management, LP | Passive13G/A | — |
| BlackRock, Inc. | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| RAPP | Common Stock | 75383L102 |